# Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

> **NCT00258258** · PHASE1 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 7 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** paricalcitol
- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT00258258
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2009-03
- **Final completion:** —
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Withdrawn due to low accrual
- **Last updated:** 2013-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258258, "Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00258258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*